The system is both radiolucent and radio visible for intra-operative and post-operative imaging. Credit: Dr Manuel González Reyes from Pixabay.

HAPPE Spine has received 510(k) clearance from the US Food and Drug Administration (FDA) for its INTEGRATE-C interbody fusion system.

INTEGRATE-C, which is powered by the Hydroxyapatite Porous Polyetheretherketone (HAPPE) platform, is claimed to be the first interbody fusion cage that is wholly integrated with porosity and hydroxyapatite to provide a better healing environment.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The interconnected and cancellous porosity facilitates the ingrowth of bone from endplate to endplate. The system is both radiolucent and radio visible for intra-operative and post-operative imaging.

Beacon Health System neurosurgeon Dr Stephen Smith said: “Our team at HAPPE is proud and excited to share this advancement with our colleagues. We have achieved our goal of developing an ACDF that’s distinguished from all other existing devices used for interbody fusion.

“The HAPPE INTEGRATE-C delivers superior radiographic visibility, optimum biomechanical properties for both load bearing and healing and true graft incorporation.”

See Also:

The INTEGRATE-C system provides various sizes and lordotic angles to meet the anatomical requirements of the patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Currently, the firm’s commercialisation strategy is focused on a limited user release to validate the product’s efficacy through clinical data.

HAPPE Spine CEO Andrew Iott said: “We are very excited to have gained 510(k) clearance for HAPPE’s new innovative technology and look forward to launching game-changing product solutions in the near future.

“The combination of cancellous porosity with hydroxyapatite exposed on all pore surfaces represents a true leap forward in interbody fusion devices.”

HAPPE Spine is engaged in the designing and commercialisation of advanced orthopaedic and spinal implants using its patented HAPPEmaterial platform.